NYSE:BSXBoston Scientific Stock Price, Forecast & News

$37.61

+0.11 (+0.29 %)

(As of 06/2/2020 11:18 AM ET)

Add

Compare

Today's Range

$37.48

Now: $37.61▼

$37.99

50-Day Range

$34.79

MA: $36.53▼

$38.29

52-Week Range

$24.10

Now: $37.61▼

$46.62

Volume168,584 shs

Average Volume10.43 million shs

Market Capitalization$52.63 billion

P/E Ratio12.37

Dividend YieldN/A

Beta0.94

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.04, and is based on 20 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.79, Boston Scientific has a potential upside of 18.5% from its current price of $37.79.
Amount of Analyst Coverage
Boston Scientific has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Boston Scientific has received 868 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Boston Scientific has received 736 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Boston Scientific has received 54.11% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote “Outperform” if you believe BSX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Boston Scientific does not currently pay a dividend.
Dividend Growth
Boston Scientific does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $562,134.00 in company stock.
Percentage Held by Insiders
Only 0.70% of the stock of Boston Scientific is held by insiders.
Percentage Held by Institutions
90.10% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1 Earnings and Valuation

Earnings Growth
Earnings for Boston Scientific are expected to grow by 84.44% in the coming year, from $0.90 to $1.66 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Boston Scientific is 12.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of Boston Scientific is 12.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.41.
Price to Earnings Growth Ratio
Boston Scientific has a PEG Ratio of 3.95. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Boston Scientific has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.07 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:BSX

Previous Symbol

CUSIP10113710

CIK885725

Webwww.bostonscientific.com

Phone508-683-4000

Debt

Debt-to-Equity Ratio0.68

Current Ratio1.21

Quick Ratio0.80

Price-To-Earnings

Trailing P/E Ratio12.37

Forward P/E Ratio41.79

P/E Growth3.95

Sales & Book Value

Annual Sales$10.74 billion

Price / Sales4.90

Cash Flow$2.38 per share

Price / Cash Flow15.81

Book Value$9.96 per share

Price / Book3.78

Profitability

EPS (Most Recent Fiscal Year)$1.58

Net Income$4.70 billion

Net Margins39.75%

Return on Equity18.24%

Return on Assets7.64%

Miscellaneous

Employees36,000

Outstanding Shares1,399,350,000

Market Cap$52.63 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19 (Coronavirus)?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BSX stock has increased by 11.6% and is now trading at $37.79. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 20 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Boston Scientific.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Boston Scientific.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) posted its quarterly earnings data on Wednesday, April, 29th. The medical equipment provider reported $0.28 EPS for the quarter, missing the Zacks' consensus estimate of $0.33 by $0.05. The medical equipment provider had revenue of $2.54 billion for the quarter, compared to analyst estimates of $2.54 billion. Boston Scientific had a return on equity of 18.24% and a net margin of 39.75%. Boston Scientific's revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS. View Boston Scientific's earnings history.

What price target have analysts set for BSX?

25 equities research analysts have issued 12-month price targets for Boston Scientific's shares. Their forecasts range from $25.00 to $58.00. On average, they anticipate Boston Scientific's stock price to reach $44.79 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price. View analysts' price targets for Boston Scientific.

Has Boston Scientific been receiving favorable news coverage?

Press coverage about BSX stock has trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Boston Scientific earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutBoston Scientific.

Who are some of Boston Scientific's key competitors?

Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Masimo (MASI) and Insulet (PODD). View all competitors.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Bank of America (BAC), CVS Health (CVS), salesforce.com (CRM), Johnson & Johnson (JNJ), AT&T (T), Home Depot (HD) and Visa (V).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:

Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 55, Pay $3.57M)
Mr. Daniel J. Brennan, Exec. VP & CFO (Age 54, Pay $1.28M)
Mr. Edward F. Mackey, Exec. VP of Operations (Age 57, Pay $1.13M)
Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 56, Pay $1.24M)
Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 47, Pay $1.07M)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital World Investors (5.77%), State Street Corp (4.45%), Wellington Management Group LLP (3.05%), Janus Henderson Group PLC (3.04%), Primecap Management Co. CA (3.02%) and JPMorgan Chase & Co. (2.68%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View institutional ownership trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Primecap Management Co. CA, Capital Research Global Investors, Invesco Ltd., and First Trust Advisors LP. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, Wendy Carruthers, and Xin Warren Wang. View insider buying and selling activity for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Viking Global Investors LP, Wellington Management Group LLP, Jennison Associates LLC, Majedie Asset Management Ltd, Janus Henderson Group PLC, Vontobel Asset Management Inc., and Fisher Asset Management LLC. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott. View insider buying and selling activity for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $37.79.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $52.88 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff